Loading...
Market
When will GSK's CMG1A46 achieve blockbuster status by end of 2027?
2
Resolution / Starting Odds
Achieves blockbuster status in 2025 • 25%
Achieves blockbuster status in 2026 • 25%
Achieves blockbuster status in 2027 • 25%
Does not achieve blockbuster status by end of 2027 • 25%
GSK financial reports and industry sales data
Story
British GSK Acquires Experimental Lupus Drug from Chimagen Biosciences for Up to $850 Million
Oct 29, 2024, 12:27 PM
British drugmaker GSK has entered into an agreement to acquire CMG1A46, an experimental drug from Chinese biotech firm Chimagen Biosciences, for up to $850 million. This acquisition includes a $300 million upfront payment and aims to expand GSK's pipeline of potential treatments for lupus. The drug, CMG1A46, is a clinical-stage dual CD19 and CD20-targeted T cell-engager, which is expected to enhance GSK's immunology portfolio.
View original story
Similar markets
Less than $100 million • 25%
$100 million - $200 million • 25%
$200 million - $300 million • 25%
More than $300 million • 25%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by more than 5% • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than $100M • 25%
$100M - $500M • 25%
$500M - $1B • 25%
More than $1B • 25%
Under $1 billion • 33%
$1 billion - $2 billion • 33%
Over $2 billion • 33%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
Increase by over 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Respiratory drug • 25%
Immunology drug • 25%
Vaccine • 25%
Other • 25%